Preventing sepsis development in complicated urinary tract infections

References

• Sabih A, Leslie SW. Complicated urinary tract infections. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan [Updated 2019 Mar 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK436013
   Google Scholar
• Kennedy JL, Haberling DL, Huang CC, et al. Infectious disease hospitalizations — United States, 2001–2014. Chest. 2019;156(2):255–268.
   PubMed Web of Science ®Google Scholar
• Foxman B, Barlow R, D’Arcy H, et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10:509–515.
   PubMed Web of Science ®Google Scholar
• Simmering JE, Tang F, Cavanaugh JE, et al. The increase in hospitalizations for urinary tract infections and the associated costs in the United States, 1998–2011. Open Forum Infect Dis. 2017;4(1):ofw281.
   PubMed Web of Science ®Google Scholar
• The Healthcare-Associated Infections Prevalence Study Group, Suetens C, Latour K, Kärki T, et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro Surveill. 2018;23(46):1800516.
   Google Scholar
• EPICStudy Group, Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380(8):729–740.
   PubMed Web of Science ®Google Scholar
• Levison ME, Kaye D. Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens. Curr Infect Dis Rep. 2013;15:109–115.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Sakr Y, Sprung CL, et al. Sepsis occurrence in acutely ill patients investigators. sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344–353.
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Lascols C, Nicolle LE, et al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009–2010. Diagn Microbiol Infect Dis. 2012;74(1):62–67.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Point prevalence survey of healthcare associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC; 2013.
   Google Scholar
• Lob SH, Hackel MA, Hoban DJ, et al. Activity of ertapenem against Enterobacteriaceae in seven global regions-SMART 2012–2016. Eur J Clin Microbiol Infect Dis. 2018;37:1481–1489.
   PubMed Web of Science ®Google Scholar
• Tenney J, Hudson N, Alnifaidy H, et al. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharm J. 2018;26(5):678–684.
   PubMed Web of Science ®Google Scholar
• Säemann M, Hörl WH. Urinary tract infection in renal transplant recipients. Eur J Clin Invest. 2008;38(Suppl 2):58–65.
   PubMedGoogle Scholar
• Vidal E, Torre-Cisneros J, Blanes M, et al. Bacterial urinary tract infection after solid organ transplantation in RESITRA cohort. Transpl Infect Dis. 2012;14(6):595–603.
   PubMed Web of Science ®Google Scholar
• Singh R, Bemelman FJ, Hodiamont CJ, et al. The impact of trimethoprim-sulfamethoxazole as pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study. BMC Infect Dis. 2016;16:90.
   PubMed Web of Science ®Google Scholar
• Alevizakos M, Nasioudis D, Mylonakis E. Urinary tract infections caused by ESBL-producing Enterobacteriaceae in renal transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. 2017;19(6):e12759.
   Web of Science ®Google Scholar
• Pinheiro HS, Mituiassu AM, Carminatti M, et al. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in kidney transplant patients. Transplant Proc. 2010;42(2):486–487.
   PubMed Web of Science ®Google Scholar
• Hounsom L, Grayson K, Melzer M. Mortality and associated risk factors in consecutive patients admitted to a UK NHS trust with community acquired bacteraemia. Postgrad Med J. 2011;87:757e62.
   Web of Science ®Google Scholar
• Shaw E, Benito N, Rodríguez-Baño J, et al. REIPI/ITUBRAS-GEIH group, Spain. Risk factors for severe sepsis in community-onset bacteraemic urinary tract infection: impact of antimicrobial resistance in a large hospitalised cohort. J Infect. 2015;70(3):247–254.
   PubMed Web of Science ®Google Scholar
• Tillmann B, Wunsch H. Epidemiology and outcomes. Crit Care Clin. 2018;34:15–27.
   PubMed Web of Science ®Google Scholar
• Lee YC, Hsiao CY, Hung MC, et al. Bacteremic urinary tract infection caused by multidrug-resistant Enterobacteriaceae are associated with severe sepsis at admission: implication for empirical therapy. Medicine (Baltimore). 2016;95(20):e3694.
   PubMed Web of Science ®Google Scholar
• Perl TM, Dvorak L, Hwang T, et al. Long-term survival and function after suspected gram-negative bacteremia. JAMA. 1995;274(4):338–345.
   PubMed Web of Science ®Google Scholar
• Thulstrup AM, Sorensen HT, Schonheyder HC, et al. Population based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis. 2000;31:1357–1361.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee YM, Cho JH. Risk factors of septic shock in bacteremic acute pyelonephritis patients admitted to an ER. J Infect Chemother. 2012;18:130–133.
   PubMed Web of Science ®Google Scholar
• Hilt EE, McKinley K, Pearce MM, et al. Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J Clin Microbiol. 2014;52(3):871–876.
   PubMed Web of Science ®Google Scholar
• Grahn D, Norman DC, White ML, et al. Validity of urinary catheter specimen for diagnosis of urinary tract infection in the elderly. Arch Intern Med. 1985;145(10):1858–1860.
   PubMedGoogle Scholar
• Wagenlehner FM, Lichtenstern C, Rolfes C, et al. Diagnosis and management for urosepsis. Int J Urol. 2013;20:963–970.
   PubMed Web of Science ®Google Scholar
• Gharbi M, Drysdale JH, Lishman H, et al. Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. BMJ. 2019;364:l525.
   PubMedGoogle Scholar
• Lee SS, Kim Y, Chung DR. Impact of discordant empirical therapy on outcome of community acquired bacteremic acute pyelonephritis. J Infect. 2011;62:159–164.
   PubMed Web of Science ®Google Scholar
• Esparcia A, Artero A, Eiros JM, et al. Influence of inadequate antimicrobial therapy on prognosis in elderly patients with severe urinary tract infection. Eur J Intern Med. 2014;25:523–527.
   PubMed Web of Science ®Google Scholar
• Babich T, Zusman Q, Elbaz M, et al. Empirical antibiotic treatment does not improve outcomes in catheter-associated urinary tract infection: prospective cohort study. Clin Infect Dis. 2017;65:1799–1805.
   PubMed Web of Science ®Google Scholar
• Eliakim-Raz, Babitch T, Shaw E, et al. Risk factors for treatment failure and mortality among hospitalized patients with complicated urinary tract infection: a multicenter retrospective cohort study (RESCUING Study Group). Clin Infect Dis. 2019;68:29–36.
   PubMed Web of Science ®Google Scholar
• Wiggers JB, Sehgal P, Pinto R, et al. The association of adequate empirical treatment and time to recovery from bacteraemic urinary tract infection: a retrospective cohort study. Clin Microbiol Infect. 2019;25(10):1253–1258.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13507.
   PubMed Web of Science ®Google Scholar
• Bodro M, Sanclemente G, Lipperheide I, et al. Impact of antibiotic resistance on the development of recurrent and relapsing symptomatic urinary tract infection in kidney recipients. Am J Transplant. 2015;15(4):1021–1027.
   PubMed Web of Science ®Google Scholar
• Tawab KA, Gheith O, Al Otaibi T, et al. Recurrent urinary tract infection among renal transplant recipients: risk factors and long-term outcome. Exp Clin Transplant. 2017;15(2):157–163.
   PubMed Web of Science ®Google Scholar
• Gozdowska J, Czerwinska M, Chabros L, et al. Urinary tract infections in kidney transplant recipients hospitalized at a transplantation and nephrology ward: 1-year follow-up. Transplant Proc. 2016;48(5):1580–1589.
   PubMed Web of Science ®Google Scholar
• Brennan DC, Daller JA, Lake KD, et al. Group TIS. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967–1977.
   PubMed Web of Science ®Google Scholar
• Giral M, Pascuariello G, Karam G, et al. Acute graft pyelonephritis and long-term kidney allograft outcome. Kidney Int. 2002;61(5):1880–1886.
   PubMed Web of Science ®Google Scholar
• Pellé G, Vimont S, Levy PP, et al. Acute pyelonephritis represents a risk factor impairing long-term kidney graft function. Am J Transplant. 2007;7(4):899–907.
   PubMed Web of Science ®Google Scholar
• EAU. Guidelines for urological infections; 2018 [cited 2019 Jun 24]. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urological-Infections-2018-large-text.pdf
   Google Scholar
• Nicolle L. Symptomatic urinary tract infection or asymptomatic bacteriuria? Improving care for the elderly. Clin Microbiol Infect. 2019;25(7):779–781.
   PubMed Web of Science ®Google Scholar
• Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the infectious diseases society of America. Clin Infect Dis. 2019;68:1611–1615.
   PubMedGoogle Scholar
• Cai T, Mazzoli S, Mondaini N, et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis. 2012;55(6):771–777.
   PubMed Web of Science ®Google Scholar
• Origüen J, López-Medrano F, Fernández-Ruiz M, et al. Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial. Am J Transplant. 2016;16(10):2943–2953.
   PubMed Web of Science ®Google Scholar
• Green H, Rahamimov R, Goldberg E, et al. Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study. Eur J Clin Microbiol Infect Dis. 2013;32(1):127–131.
   PubMed Web of Science ®Google Scholar
• El Amari EB, Hadaya K, Bühler L, et al. Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. Nephrol Dial Transplant. 2011;26(12):4109–4114.
   PubMed Web of Science ®Google Scholar
• Moradi M, Abbasi M, Moradi A, et al. Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients. Urol J. 2005;2(1):32–35.
   PubMedGoogle Scholar
• Nevo A, Golomb D, Lifshitz D, et al. Predicting the risk of sepsis and causative organisms following urinary stones removal using urinary versus stone and stent cultures. Eur J Clin Microbiol Infect Dis. 2019;38(7):1313–1318.
   PubMed Web of Science ®Google Scholar
• Bodro M, Linares L, Chiang D, et al. Managing recurrent urinary tract infections in kidney transplant patients. Expert Rev Anti Infect Ther. 2018;16(9):723–732.
   PubMed Web of Science ®Google Scholar
• Dinckan A, Aliosmanoglu I, Kocak H, et al. Surgical correction of vesico-ureteric reflux for recurrent febrile urinary tract infections after kidney transplantation. BJU Int. 2013;112(4):E366–71.
   PubMed Web of Science ®Google Scholar
• Albert X, Huertas I, Pereiró II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004:1–58. CD001209(3).
   PubMed Web of Science ®Google Scholar
• Eells SJ, Bharadwa K, McKinnell JA, et al. Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model. Clin Infect Dis. 2014;58(2):147–160.
   PubMed Web of Science ®Google Scholar
• Muñoz P. Management of urinary tract infections and lymphocele in renal transplant recipients. Clin Infect Dis. 2001;33(Suppl 1):S53–7.
   PubMedGoogle Scholar
• Parasuraman R, Julian K. AST infectious diseases community of practice. Urinary tract infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):327–336.
   PubMedGoogle Scholar
• de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol. 2008;4(5):252–264.
   PubMedGoogle Scholar
• Abrams P, Hashim H, Tomson C, et al. The use of intravesical gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunction. Neurourol Urodyn. 2017;36(8):2109–2116.
   PubMed Web of Science ®Google Scholar
• Stalenhoef JE, van der Starre WE, Vollaard AM, et al. Hospitalization for community-acquired febrile urinary tract infection: validation and impact assessment of a clinical prediction rule. BMC Infect Dis. 2017;17(1):400.
   PubMedGoogle Scholar
• Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the infectious diseases society of America. Clin Infect Dis. 2010;50(5):625–663.
   PubMed Web of Science ®Google Scholar
• Wise GJ, Schlegel PN. Sterile pyuria. N Engl J Med. 2015;372:1048–1054.
   PubMed Web of Science ®Google Scholar
• UK standards for Microbiology Investigations. Investigation of urine.Issued by the Standards Unit, Microbiology Services, PHE Bacteriology | B 41 | Issue no: 8.7 | Issue date: 11. 01.19. [cited from 2019 Dec 6]. Available at: http://www.apsi.it/public/ufiles/smi/b41_8_7_en_190111.pdf.
   Google Scholar
• Stamm WE, Counts GW, Running KR, et al. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med. 1982;307:463–468.
   PubMed Web of Science ®Google Scholar
• Kunin CM, White LV, Hua TH. A reassessment of the importance of “low-count” bacteriuria in young women with acute urinary symptoms. Ann Intern Med. 1993;119:454–460.
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–1596.
   PubMed Web of Science ®Google Scholar
• Karve S, Ryan K, Peeters P, et al. The impact of initial antibiotic treatment failure: real-world insights in patients with complicated urinary tract infection. J Infect. 2018;76(2):121–131.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, et al. 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study. Antimicrob Resist Infect Control. 2017;6:124.
   PubMed Web of Science ®Google Scholar
• Reyner K, Heffner AC, Karvetski CH. Urinary obstruction is an important complicating factor in patients with septic shock due to urinary infection. Am J Emerg Med. 2016;34:694–696.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.
   PubMed Web of Science ®Google Scholar
• Fourcade RO. Antibiotic prophylaxis with cefotaxime in endoscopic extraction of upper urinary tract stones: a randomized study. The Cefotaxime Cooperative Group. J Antimicrob Chemother. 1990;26(Suppl. A):77–83.
   PubMedGoogle Scholar
• Grabe M. Controversies in antibiotic prophylaxis in urology. Int J Antimicrob Agents. 2004;23(Suppl. 1):S17–23.
   PubMed Web of Science ®Google Scholar
• Hsieh CH, Yang SS, Lin CD, et al. Are prophylactic antibiotics necessary in patients with preoperative sterile urine undergoing ureterorenoscopic lithotripsy? BJU Int. 2014;113(2):275–280.
   PubMed Web of Science ®Google Scholar
• Kahan FM, Kahan JS, Cassidy PJ, et al. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974;235:364–386.
   PubMed Web of Science ®Google Scholar
• Grabein B, Graninger W, Rodríguez Baño J, et al. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017;23(6):363–372.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Infect. 2016;29(2):321–347.
   Google Scholar
• Pea F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol. 2013;8(1):5–12.
   PubMedGoogle Scholar
• Parker SL, Frantzeskaki F, Wallis SC, et al. Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob Agents Chemother. 2015;59(10):6471–6476.
   PubMed Web of Science ®Google Scholar
• EUCAST clinical breakpoint and dosing of antibiotics. [cited 2019 Jul 01]. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf
   Google Scholar
• Docobo-Pérez F, Drusano GL, Johnson A, et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother. 2015;59(9):5602–5610.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Shen P, Wei Z, et al. Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China. Int J Antimicrob Agents. 2015;45(1):66–70.
   PubMed Web of Science ®Google Scholar
• Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43(1):52–59.
   PubMed Web of Science ®Google Scholar
• de Cueto M, López L, Hernández JR, et al. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother. 2006;50(1):368–370.
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Raux BR, Zucchi PC, et al. Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates. Int J Antimicrob Agents. 2015;46(6):642–647.
   PubMed Web of Science ®Google Scholar
• Kaase M, Szabados F, Anders A, et al. Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. J Clin Microbiol. 2014;52(6):1893–1897.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Rice LB, Dane A, et al. Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis. 2019;69(12):2045–2056.
   Web of Science ®Google Scholar
• Bland CM, Pai MP, Lodise TP. Reappraisal of contemporary Pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing. Pharmacotherapy. 2018;38(12):1229–1238.
   PubMed Web of Science ®Google Scholar
• South Australian Expert Advisory Group on Antimicrobial Resistance (SAAGAR). Aminoglycoside: recommendations for use, dosing and monitoring clinical guideline. [cited 2019 Jul 01]. Available from: www.sahealth.sa.gov.au/wps/wcm/connect/e4c8cb004877c5c3a295f67675638bd8/Aminoglycosides_01062017.pdf?MOD=AJPERES&CACHEID=ROOTWORKSPACE-e4c8cb004877c5c3a295f67675638bd8-lNRygVY
   Google Scholar
• Denervaud-Tendon V, Poirel L, Connolly LE. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates. J Antimicrob Chemother. 2017;72(10):2787–2791.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Hujer KM, Hujer AM, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2009;53(10):4504–4507.
   PubMed Web of Science ®Google Scholar
• Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23(10):704–712.
   PubMed Web of Science ®Google Scholar
• Aggen JB, Armstrong ES, Goldblum AA, et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother. 2010;54(11):4636–4642.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011;66(1):48–53.
   PubMed Web of Science ®Google Scholar
• Galani I, Souli M, Daikos GL, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother. 2012;24(4):191–194.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/ß-lactamase inhibitor combination. Drugs. 2013;73(2):159–177.
   PubMed Web of Science ®Google Scholar
• Sherry N, Howden B. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications. Expert Rev Anti Infect Ther. 2018;16(4):289–306.
   PubMed Web of Science ®Google Scholar
• Gardiner BJ, Golan Y. Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections. Expert Rev Anti Infect Ther. 2016;14(5):451–463.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Zaficefta (ceftazidime/avibactam). [cited 2019 Jul 01]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004027/human_med_001993.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71(10):2713–2722.
   PubMed Web of Science ®Google Scholar
• Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017;61(2):e01964–16.
   PubMed Web of Science ®Google Scholar
• Shirley M. Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections. Drugs. 2018;78(6):675–692.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63(6):754–762.
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661–673.
   PubMed Web of Science ®Google Scholar
• Davido B, Fellous L, Lawrence C, et al. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome b-lactam resistance conferred by metallo-b-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61(9):e01008–17.
   PubMed Web of Science ®Google Scholar
• Jayol A, Nordmann P, Poirel L, et al. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73(2):542–544.
   PubMed Web of Science ®Google Scholar
• Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3):e02097–16.
   PubMed Web of Science ®Google Scholar
• Giddins MJ, Macesic N, Annavajhala MK, et al. Successive emergence of ceftazidime- avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62(3):e02101–17.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Bassetti M, De Rosa FG, et al. Ceftolozane/tazobactam: place in therapy. Expert Rev Anti Infect Ther. 2018;16(4):307–320.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385(9981):1949–1956.
   PubMed Web of Science ®Google Scholar
• Huntington JA, Sakoulas G, Umeh O, et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother. 2016;71(7):2014–2021.
   PubMed Web of Science ®Google Scholar
• Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem. 2015;58(9):3682–3692.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11):e01443–17.
   PubMed Web of Science ®Google Scholar
• The Medicines Company. VABOMERE™ (meropenem and vaborbactam): US prescribing information; 2018 [cited 2019 Jul 01]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209776s001lbl.pdf
   Google Scholar
• [cited 2019 May 01]. Available from: www.ema.europa.eu/documents/smop-initial/summary-opinion-vabomere_en.pdf
   Google Scholar
• Rubino CM, Bhavnani SM, Loutit JS, et al. Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment. Antimicrob Agents Chemother. 2018;62(3):e02103–17.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788–799.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439–455.
   PubMed Web of Science ®Google Scholar
• Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(12):e01694–17.
   PubMed Web of Science ®Google Scholar
• Sabet M, Tarazi Z, Rubio-Aparicio D, et al. Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow-fiber model. Antimicrob Agents Chemother. 2018;62(2):e01969–17.
   PubMed Web of Science ®Google Scholar
• Kohira N, West J, Ito A, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2016;60(2):729–734.
   PubMed Web of Science ®Google Scholar
• Ito A, Nishikawa T, Matsumoto S, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(12):7396–7401.
   PubMed Web of Science ®Google Scholar
• Saisho Y, Katsube T, White S, et al. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 2018;62(3):e02163–17.
   PubMed Web of Science ®Google Scholar
• Dobias J, Dénervaud-Tendon V, Poirel L, et al. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017;36(12):2319–2327.
   PubMed Web of Science ®Google Scholar
• Linsenmeyer TA. Catheter-associated urinary tract infections in persons with neurogenic bladders. J Spinal Cord Med. 2018;41(2):132–141.
   PubMed Web of Science ®Google Scholar
• Ernstsen CL, Login FH, Jensen HH, et al. Detection and quantification of intracellular bacterial colonies by automated, high-throughput microscopy. J Microbiol Methods. 2017;139:37–44.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Regional outbreak of New Delhi metallo-beta-lactamase producing carbapenem-resistant Enterobacteriaceae, Italy, 2018–2019 – 4 June 2019. ECDC: Stockholm; 2019 [cited 2019 Jun 27]. Available from: https://www.ecdc.europa.eu/sites/portal/files/documents/04-Jun-2019-RRA-Carbapenems%2C%20Enterobacteriaceae-Italy.pdf
   Google Scholar
• Motley MP, Fries BC. A new take on an old remedy: generating antibodies against multidrug-resistant Gram-negative bacteria in a postantibiotic world. mSphere. 2018;2(5):e00397–17.
   Web of Science ®Google Scholar
• Huttner A, Hatz C, van den Dobbelsteen G, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017;17(5):528–537.
   PubMed Web of Science ®Google Scholar
• Ujmajuridze A, Chanishvili N, Goderdzishvili M, et al. Adapted bacteriophages for treating urinary tract infections. Front Microbiol. 2018;9:1832.
   PubMed Web of Science ®Google Scholar
• Darouiche RO, Green BG, Donovan WH, et al. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology. 2011;78(2):341–346.
   PubMedGoogle Scholar